価格表

在庫・価格 : 2026年04月06日 18時40分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-TRAIL-R2, Rabbit-Poly
データシート
NB100-56618 NOVノバス バイオロジカルス
Novus biologicals, LLC
0.1 mg ¥96,000
(未発注)
追加

在庫・価格 : 2026年04月06日 18時40分 現在

Anti-TRAIL-R2, Rabbit-Poly

  • 商品コード:NB100-56618
  • メーカー:NOV
  • 包装:0.1mg
  • 価格: ¥96,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Zhang X et al. Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest. Ophthalmol. Vis. Sci. 2011 Aug;52(9):6279-85
Zhang X et al
2011/01/01
Species: Mouse, Applications: IHC, ICC/IF PubMed
2 Georgakis GV et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
Georgakis GV et al
2005/01/01
PubMed
3 Zou W et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004 Oct;
Zou W et al
2004/01/01
PubMed
4 Abdelrahim M et al. 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006 Apr;27(4):717-28
Abdelrahim M et al
2006/01/01
PubMed
5 Xu J et al. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006 Oct;66(20):10092-9
Xu J et al
2006/01/01
PubMed
6 Fan QL et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother. Pharmacol. 2005 Feb;55(2):189-96
Fan QL et al
2005/01/01
PubMed
7 Jane EP et al. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 2011 Jan;10(1):198-208
Jane EP et al
2011/01/01
PubMed
8 Song JH et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci. 2006 Mar;26(12):3299-308
Song JH et al
2006/01/01
PubMed
9 Burns TF et al. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001 Aug;20(34):4601-12
Burns TF et al
2001/01/01
PubMed
10 Wang S et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 2010 May;16(9):2591-604
Wang S et al
2010/01/01
PubMed
11 Kim K et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000 Feb;6(2):335-46
Kim K et al
2000/01/01
PubMed
12 Zhang HG et al. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J. Virol. 2002 Jun;76(11):5692-700
Zhang HG et al
2002/01/01
PubMed
13 Allen JE et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol. Cancer Ther. 2012 Oct;11(10):2087-95
Allen JE et al
2012/01/01
PubMed
14 Xu J et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008 Aug;68(16):6718-26
Xu J et al
2008/01/01
PubMed
15 Xu J et al. Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 2013 Nov;288(46):33263-71
Xu J et al
2013/01/01
PubMed
16 Qiu F et al. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep 2013;3:3565
Qiu F et al
2013/01/01
PubMed
17 Kusaba M et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007 Oct;47(4):546-55
Kusaba M et al
2007/01/01
PubMed
18 Basile JR et al. The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J.
Basile JR et al
2001/01/01
Species: Human, Applications: WB PubMed
19 Younes M et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur. J. Cancer 2006 Mar;42(4):542-7
Younes M et al
2006/01/01
Applications: WB, IHC-P, Flow-CS PubMed
20 Koyama S. Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis. J. Gastroenterol. Hepatol. 2003 Jul;
Koyama S
2003/01/01
Applications: Flow-CS PubMed
21 Xu J et al. The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling. Cell Cycle 2014;13(23):3750-8
Xu J et al
2014/01/01
Species: Human, Applications: WB PubMed
22 Prabhu VV et al. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015 Apr;75(7):1423-32
Prabhu VV et al
2015/01/01
Species: Human, Applications: FLOW PubMed
23 Liu Y et al. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin. Cancer Res. 2015 Dec;21(23):5338-48
Liu Y et al
2015/01/01
Species: Human, Applications: WB PubMed
24 Talekar MK et al. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle 2015 Aug;14(15):2422-8
Talekar MK et al
2015/01/01
Applications: FLOW PubMed
25 Foster KA et al. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int. J. Oncol. 2015 Aug;47(2):506-16
Foster KA et al
2015/01/01
Species: Human, Applications: ICC/IF PubMed
26 Di X et al. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 2013 Sep;4(9):1349-64
Di X et al
2013/01/01
Applications: ICC/IF PubMed
27 Abdulghani J et al. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS ONE 2013;8(9):e75414
Abdulghani J et al
2013/01/01
Species: Human, Applications: FLOW PubMed
28 Allen JE et al. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS ONE 2015;10(11):e0143082
Allen JE et al
2015/01/01
PubMed
29 Chen JJ et al. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget 2014 Jul;5(13):5125-37
Chen JJ et al
2014/01/01
PubMed
30 Kandasamy K et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer
Kandasamy K et al
2003/01/01
PubMed
31 Cuello M et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001 Jun;61(
Cuello M et al
2001/01/01
PubMed
32 Jin Z et al. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 2004 Aug;279(34):35829-39
Jin Z et al
2004/01/01
PubMed
33 Koyama S et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 2002 Feb;128(2):73-9
Koyama S et al
2002/01/01
PubMed
34 Dandrea T et al. The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation. Free Radic. Biol. Med. 2004 Apr;36(7):881-96
Dandrea T et al
2004/01/01
PubMed
35 Kim K et al. Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ. 2004 May;11(5):583-7
Kim K et al
2004/01/01
PubMed
36 Eid MA et al. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol. Cancer Ther. 2002 Aug;1(10):831-40
Eid MA et al
2002/01/01
PubMed
37 Shin GC et al. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy 2016 Dec;12(12):2451-2466
Shin GC et al
2016/01/01
Species: Human, Applications: WB, IHC PubMed
38 Xue M et al. Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep 2017 Jul;16(1):978-982
Xue M et al
2017/01/01
PubMed
39 Stein MN et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 2019 05;7(1):136
Stein MN et al
2019/01/01
PubMed
40 Chen L et al. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. J Biol Chem ;296:100515
Chen L et al
PubMed
41 Arrillaga-Romany I et al. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol 2020 01;22(1):94-102
Arrillaga-Romany I et al
2020/01/01
PubMed
  • No.: 1
  • 文献情報:
    Zhang X et al. Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest. Ophthalmol. Vis. Sci. 2011 Aug;52(9):6279-85
    Zhang X et al
    2011/01/01
  • 備考:
    Species: Mouse, Applications: IHC, ICC/IF
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Georgakis GV et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Zou W et al. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004 Oct;
    Zou W et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Abdelrahim M et al. 3,3'-diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006 Apr;27(4):717-28
    Abdelrahim M et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Xu J et al. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alpha-mediated sensitization of human breast cancer cells to chemotherapy. Cancer Res. 2006 Oct;66(20):10092-9
    Xu J et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Fan QL et al. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother. Pharmacol. 2005 Feb;55(2):189-96
    Fan QL et al
    2005/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Jane EP et al. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 2011 Jan;10(1):198-208
    Jane EP et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Song JH et al. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J. Neurosci. 2006 Mar;26(12):3299-308
    Song JH et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Burns TF et al. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001 Aug;20(34):4601-12
    Burns TF et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Wang S et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 2010 May;16(9):2591-604
    Wang S et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Kim K et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000 Feb;6(2):335-46
    Kim K et al
    2000/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Zhang HG et al. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver. J. Virol. 2002 Jun;76(11):5692-700
    Zhang HG et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Allen JE et al. Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes. Mol. Cancer Ther. 2012 Oct;11(10):2087-95
    Allen JE et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Xu J et al. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008 Aug;68(16):6718-26
    Xu J et al
    2008/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Xu J et al. Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 2013 Nov;288(46):33263-71
    Xu J et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Qiu F et al. Annexin V-TRAIL fusion protein is a more sensitive and potent apoptotic inducer for cancer therapy. Sci Rep 2013;3:3565
    Qiu F et al
    2013/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Kusaba M et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007 Oct;47(4):546-55
    Kusaba M et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Basile JR et al. The cytokines tumor necrosis factor-alpha (TNF-alpha ) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J.
    Basile JR et al
    2001/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Younes M et al. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur. J. Cancer 2006 Mar;42(4):542-7
    Younes M et al
    2006/01/01
  • 備考:
    Applications: WB, IHC-P, Flow-CS
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Koyama S. Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis. J. Gastroenterol. Hepatol. 2003 Jul;
    Koyama S
    2003/01/01
  • 備考:
    Applications: Flow-CS
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Xu J et al. The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signaling. Cell Cycle 2014;13(23):3750-8
    Xu J et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Prabhu VV et al. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer Res. 2015 Apr;75(7):1423-32
    Prabhu VV et al
    2015/01/01
  • 備考:
    Species: Human, Applications: FLOW
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Liu Y et al. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models. Clin. Cancer Res. 2015 Dec;21(23):5338-48
    Liu Y et al
    2015/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Talekar MK et al. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle 2015 Aug;14(15):2422-8
    Talekar MK et al
    2015/01/01
  • 備考:
    Applications: FLOW
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Foster KA et al. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int. J. Oncol. 2015 Aug;47(2):506-16
    Foster KA et al
    2015/01/01
  • 備考:
    Species: Human, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Di X et al. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 2013 Sep;4(9):1349-64
    Di X et al
    2013/01/01
  • 備考:
    Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Abdulghani J et al. Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS ONE 2013;8(9):e75414
    Abdulghani J et al
    2013/01/01
  • 備考:
    Species: Human, Applications: FLOW
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Allen JE et al. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS ONE 2015;10(11):e0143082
    Allen JE et al
    2015/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Chen JJ et al. H-Ras regulation of TRAIL death receptor mediated apoptosis. Oncotarget 2014 Jul;5(13):5125-37
    Chen JJ et al
    2014/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Kandasamy K et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer
    Kandasamy K et al
    2003/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Cuello M et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001 Jun;61(
    Cuello M et al
    2001/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Jin Z et al. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 2004 Aug;279(34):35829-39
    Jin Z et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Koyama S et al. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor. J. Cancer Res. Clin. Oncol. 2002 Feb;128(2):73-9
    Koyama S et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 34
  • 文献情報:
    Dandrea T et al. The transcriptosomal response of human A549 lung cells to a hydrogen peroxide-generating system: relationship to DNA damage, cell cycle arrest, and caspase activation. Free Radic. Biol. Med. 2004 Apr;36(7):881-96
    Dandrea T et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 35
  • 文献情報:
    Kim K et al. Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9. Cell Death Differ. 2004 May;11(5):583-7
    Kim K et al
    2004/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 36
  • 文献情報:
    Eid MA et al. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). Mol. Cancer Ther. 2002 Aug;1(10):831-40
    Eid MA et al
    2002/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 37
  • 文献情報:
    Shin GC et al. Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy 2016 Dec;12(12):2451-2466
    Shin GC et al
    2016/01/01
  • 備考:
    Species: Human, Applications: WB, IHC
  • 参照:
    PubMed
  • No.: 38
  • 文献情報:
    Xue M et al. Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep 2017 Jul;16(1):978-982
    Xue M et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 39
  • 文献情報:
    Stein MN et al. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 2019 05;7(1):136
    Stein MN et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 40
  • 文献情報:
    Chen L et al. Citrus-derived DHCP inhibits mitochondrial complex II to enhance TRAIL sensitivity via ROS-induced DR5 upregulation. J Biol Chem ;296:100515
    Chen L et al
  • 備考:
  • 参照:
    PubMed
  • No.: 41
  • 文献情報:
    Arrillaga-Romany I et al. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol 2020 01;22(1):94-102
    Arrillaga-Romany I et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed